| Product Code: ETC6661575 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 | |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Canada Multiple System Atrophy (MSA) Market Overview |
3.1 Canada Country Macro Economic Indicators |
3.2 Canada Multiple System Atrophy (MSA) Market Revenues & Volume, 2021 & 2031F |
3.3 Canada Multiple System Atrophy (MSA) Market - Industry Life Cycle |
3.4 Canada Multiple System Atrophy (MSA) Market - Porter's Five Forces |
3.5 Canada Multiple System Atrophy (MSA) Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.6 Canada Multiple System Atrophy (MSA) Market Revenues & Volume Share, By Diagnosis, 2021 & 2031F |
4 Canada Multiple System Atrophy (MSA) Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Rising prevalence of multiple system atrophy (MSA) in Canada |
4.2.2 Increasing awareness about MSA among healthcare professionals and patients |
4.2.3 Technological advancements in diagnostic tools and treatment options for MSA patients |
4.3 Market Restraints |
4.3.1 Limited treatment options available for MSA |
4.3.2 High cost associated with MSA management and treatment |
4.3.3 Lack of definitive diagnostic tests for early detection of MSA |
5 Canada Multiple System Atrophy (MSA) Market Trends |
6 Canada Multiple System Atrophy (MSA) Market, By Types |
6.1 Canada Multiple System Atrophy (MSA) Market, By Type |
6.1.1 Overview and Analysis |
6.1.2 Canada Multiple System Atrophy (MSA) Market Revenues & Volume, By Type, 2021- 2031F |
6.1.3 Canada Multiple System Atrophy (MSA) Market Revenues & Volume, By Parkinsonian, 2021- 2031F |
6.1.4 Canada Multiple System Atrophy (MSA) Market Revenues & Volume, By Cerebellar, 2021- 2031F |
6.2 Canada Multiple System Atrophy (MSA) Market, By Diagnosis |
6.2.1 Overview and Analysis |
6.2.2 Canada Multiple System Atrophy (MSA) Market Revenues & Volume, By Magnetic Resonance Imaging (MRI), 2021- 2031F |
6.2.3 Canada Multiple System Atrophy (MSA) Market Revenues & Volume, By Positron Emission Tomography (PET), 2021- 2031F |
6.2.4 Canada Multiple System Atrophy (MSA) Market Revenues & Volume, By Single Photon Emission Computed Tomography (SPECT), 2021- 2031F |
6.2.5 Canada Multiple System Atrophy (MSA) Market Revenues & Volume, By Tilt Table Test, 2021- 2031F |
6.2.6 Canada Multiple System Atrophy (MSA) Market Revenues & Volume, By Others, 2021- 2031F |
7 Canada Multiple System Atrophy (MSA) Market Import-Export Trade Statistics |
7.1 Canada Multiple System Atrophy (MSA) Market Export to Major Countries |
7.2 Canada Multiple System Atrophy (MSA) Market Imports from Major Countries |
8 Canada Multiple System Atrophy (MSA) Market Key Performance Indicators |
8.1 Average time from symptom onset to diagnosis |
8.2 Number of clinical trials focused on MSA treatments in Canada |
8.3 Adoption rate of new MSA treatment guidelines by healthcare providers |
9 Canada Multiple System Atrophy (MSA) Market - Opportunity Assessment |
9.1 Canada Multiple System Atrophy (MSA) Market Opportunity Assessment, By Type, 2021 & 2031F |
9.2 Canada Multiple System Atrophy (MSA) Market Opportunity Assessment, By Diagnosis, 2021 & 2031F |
10 Canada Multiple System Atrophy (MSA) Market - Competitive Landscape |
10.1 Canada Multiple System Atrophy (MSA) Market Revenue Share, By Companies, 2024 |
10.2 Canada Multiple System Atrophy (MSA) Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |